ASCO 2018: Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
7 Jun, 2018 | 02:19h | UTCCommentary: Ibrutinib/Rituximab Improves PFS in Waldenström’s Macroglobulinemia – ASCO Daily News (free)
Commentary: Ibrutinib/Rituximab Improves PFS in Waldenström’s Macroglobulinemia – ASCO Daily News (free)